clinical trial · NCT05993299
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)·phase2·completed·n = 7
NeoplasmsLetetresgene autoleucelCyclophosphamideFludarabine
brief summary
This trial will evaluate safety and efficacy of human engineered T-cell therapies, in participants with advanced tumors. This trial is a sub study of the Master study NCT03967223.
started
Dec 31, 2019
primary completion
Oct 12, 2022
completion
Mar 17, 2026
last updated
Sep 2, 2026
official title
Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol